Allogene Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2018 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Allogene Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2018 to Q2 2024.
  • Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $5.07M, a 288% increase year-over-year.
  • Allogene Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $9.62M.
  • Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $472K.
  • Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2022 was -$4.88M, a 162% decline from 2021.
  • Allogene Therapeutics, Inc. annual Nonoperating Income (Expense) for 2021 was -$1.86M, a 96.8% increase from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $9.62M $5.07M +$3.77M +288% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $5.85M $4.5M +$5.38M Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $472K -$669K +$211K +24% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $261K $709K +$2.44M Jul 1, 2023 Sep 30, 2023 10-K 2024-03-14
Q2 2023 -$2.18M $1.31M +$4.98M Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$7.16M -$876K -$2.28M -162% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$4.88M -$880K +$742K +45.7% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 -$5.62M -$1.73M -$1.22M -235% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-14
Q2 2022 -$4.41M -$3.67M -$3.77M -4051% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-14
Q1 2022 -$638K $1.41M +$1.22M +656% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-14
Q4 2021 -$1.86M -$1.62M +$63.7M +97.5% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 -$65.6M -$516K -$2.36M -128% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$63.2M $93K -$2.09M -95.7% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 -$61.2M $186K -$3.02M -94.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$58.1M -$65.4M -$68.8M -2028% Oct 1, 2020 Dec 31, 2020 10-K/A 2024-03-14
Q3 2020 $10.6M $1.84M -$2.47M -57.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $13.1M $2.18M -$2.38M -52.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 $15.5M $3.2M -$1.62M -33.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 $17.1M $3.39M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-23
Q3 2019 $4.31M +$25.6M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 $4.56M Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $4.83M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q3 2018 -$21.3M Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.